Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.
Histamine H(1) and serotonin 5-HT(2A) receptors present in the CNS have been implicated in various neuropsychiatric disorders. 9-Aminomethyl-9,10-dihydroanthracene (AMDA), a conformationally constrained diarylalkyl amine derivative, has affinity for both of these receptors. A structure-affinity relationship (SAFIR) study was carried out studying the effects of N-methylation, varying the linker chain length and constraint of the aromatic rings on the binding affinities of the compounds with the 5-HT(2A) and H(1) receptors. Homology modeling of the 5-HT(2A) and H(1) receptors suggests that AMDA and its analogs, the parent of which is a 5-HT(2A) antagonist, can bind in a fashion analogous to that of classical H(1) antagonists whose ring systems are oriented toward the fifth and sixth transmembrane helices. The modeled orientation of the ligands are consistent with the reported site-directed mutagenesis data for 5-HT(2A) and H(1) receptors and provide a potential explanation for the selectivity of ligands acting at both receptors.
Shah
Jitesh R
JR
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, PO Box 980540, Richmond, VA 23298, USA.
Mosier
Philip D
PD
Roth
Bryan L
BL
Kellogg
Glen E
GE
Westkaemper
Richard B
RB
D000595:Amino Acid Sequence; D000873:Anthracenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011485:Protein Binding; D011487:Protein Conformation; D044402:Receptor, Serotonin, 5-HT2A / Q000737:chemistry* / Q000378:metabolism*; D011969:Receptors, Histamine H1 / Q000737:chemistry* / Q000378:metabolism*; D016415:Sequence Alignment; D013329:Structure-Activity Relationship
C122082:9-(aminomethyl)-9,10-dihydroanthracene; D000873:Anthracenes; D044402:Receptor, Serotonin, 5-HT2A; D011969:Receptors, Histamine H1
Sleep Med Rev. 2002 Apr;6(2):97-111
12531146
Prog Neurobiol. 1997 Jun;52(2):145-57
9185237
Mol Pharmacol. 1997 Aug;52(2):259-66
9271348
Protein Eng. 1993 Jan;6(1):37-40
8433969
J Neurosci. 2002 Sep 1;22(17):7695-711
12196593
Proteins. 2003 Jan 1;50(1):5-25
12471595
Clin Exp Allergy. 1999 Jul;29 Suppl 3:19-28
10444208
Biochemistry. 1998 Jan 27;37(4):998-1006
9454590
J Org Chem. 2002 Jul 12;67(14):5028-31
12098332
J Biol Chem. 1999 Oct 15;274(42):29994-30000
10514483
Jpn J Pharmacol. 1997 Apr;73(4):291-8
9165365
J Biol Chem. 1996 Jun 21;271(25):14672-5
8663249
Arch Pharm (Weinheim). 2005 Jun;338(5-6):248-59
15952243
Mini Rev Med Chem. 2007 Nov;7(11):1108-19
18045214
Eur J Pharmacol. 1999 Sep 3;380(1):R5-7
10513561
J Org Chem. 1972 Jul 14;37(14):2347-9
5040380
J Mol Biol. 1997 Apr 4;267(3):727-48
9126849
J Med Chem. 2002 Jun 6;45(12):2469-83
12036355
Trends Pharmacol Sci. 2005 Sep;26(9):462-9
16054239
J Comput Aided Mol Des. 1991 Dec;5(6):545-52
1818090
Bioorg Med Chem. 2005 Feb 1;13(3):895-908
15653355
Eur J Pharmacol. 1998 Mar 12;345(1):111-7
9593602
Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6
11229772
Nucleic Acids Res. 2003 Jul 1;31(13):3497-500
12824352
Ann Pharm Fr. 2007 Jul;65(4):268-74
17652996
J Pharmacol Exp Ther. 1997 Feb;280(2):576-83
9023266
J Med Chem. 2002 Apr 11;45(8):1656-64
11931619
J Med Chem. 1971 Feb;14(2):161-4
5544405
Science. 2007 Nov 23;318(5854):1258-65
17962520
CNS Neurol Disord Drug Targets. 2007 Feb;6(1):31-43
17305552
J Neurosci. 2005 Dec 7;25(49):11231-8
16339018
Bioorg Med Chem Lett. 2001 Mar 12;11(5):655-8
11266163
Drugs. 2001;61(2):207-36
11270939
Evol Bioinform Online. 2007 Sep 26;3:357-70
19468313
Mol Pharmacol. 1995 Mar;47(3):450-7
7700242
Mol Pharmacol. 1993 May;43(5):755-61
8388989
Annu Rev Med. 2009;60:355-66
19630576
J Org Chem. 2003 Dec 12;68(25):9678-86
14656094
J Struct Biol. 2005 May;150(2):126-43
15866736
Clin Pharmacokinet. 1999 May;36(5):329-52
10384858
J Med Chem. 2008 Nov 13;51(21):6808-28
18847250